O'Loughlin Steve 4
4 · Actinium Pharmaceuticals, Inc. · Filed Sep 3, 2021
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-09-01+107,463→ 107,463 totalExercise: $6.07Exp: 2031-09-01→ Common Stock (107,463 underlying)
Footnotes (2)
- [F1]This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.
- [F2]Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.